“If the knowledge offered is robust sufficient to attract conclusions in regards to the high quality, security and efficacy of the vaccine, the EMA will finalize its evaluation at a particular assembly scheduled for December 29 on the newest,” he mentioned in an announcement. communicated the European company, writes Agerpres.

The company mentioned the date could possibly be modified if the information turned accessible sooner.

The Pfizer vaccine is 95% efficient, based on the outcomes of scientific trials. This vaccine could possibly be licensed earlier within the US and the UK.

Moderna has additionally utilized for the authorization of its experimental vaccine in Europe. The EMA has introduced that it’s going to resolve as early as January 12 whether or not or to not authorize the vaccine developed by the American firm Moderna, experiences the Related Press.

The American firm Moderna requested on Monday the emergency authorization of its vaccine in opposition to COVID-19, each in the USA and in Europe, based mostly on the whole outcomes of its scientific research, which exhibits that the vaccine has an effectivity of 94.1% and never has critical security issues, Reuters experiences.